| Brandon J Child, DPM | |
|
820 N Chelan Ave, Wenatchee, WA 98801-2028 | |
| (509) 663-8711 | |
| Not Available |
| Full Name | Brandon J Child |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 19 Years |
| Location | 820 N Chelan Ave, Wenatchee, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477728020 | NPI | - | NPPES |
| 8947143 | Other | WA | CV |
| P00658452 | Other | WA | RR MEDICARE |
| 1477728020 | Medicaid | WA | |
| 315587 | Other | WA | L&I POST 7/21/13 |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | PO00000837 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Washington Hospital | Wenatchee, WA | Hospital |
| Lake Chelan Community Hospital | Chelan, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Washington Health Services Association | 4880504596 | 645 |
News Archive
Liquidia Technologies today announced a collaboration with the PATH Malaria Vaccine Initiative (MVI) to explore the use of the company's PRINT® particle technology to design next generation malaria vaccines. PRINT technology offers unprecedented control of particle size, shape and chemistry in a highly consistent and scalable manufacturing process, and will be used to deliver a protein in combination with immune stimulating molecules.
University Hospitals Case Medical Center is the first in Cleveland to implant a new type of cochlear device for adults who have lost the high frequency range of their hearing, but have retained the low frequencies with or without a hearing aid.
The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).
The proposed link between caffeine and reductions in the beta amyloid plaque accumulation characteristic of Alzheimer's disease (AD) suggest a possible role for caffeine in AD treatment. The latest evidence linking beta amyloid protein to Alzheimer's disease and exploring the relationship between caffeine and beta amyloid are featured in a review article in Journal of Caffeine Research: The International Multidisciplinary Journal of Caffeine Science, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Three years ago, the research team directed by Óscar Fernández-Capetillo, head of the Genomic Instability Group at the Spanish National Cancer Research Centre, obtained, for the first time, a panoramic view of the proteins that intervene in one of the most important and delicate cellular processes: the copying of genetic material during cellular division. They observed that the parts of the genome where the DNA was copied were also very rich in the modification by some very particular proteins, SUMOylations, and poor in others, ubiquitinations, but they were unable to understand why.
› Verified 8 days ago
| Provider Name | Central Washington Health Services Association |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1801937453 PECOS PAC ID: 4880504596 Enrollment ID: O20031106000287 |
News Archive
Liquidia Technologies today announced a collaboration with the PATH Malaria Vaccine Initiative (MVI) to explore the use of the company's PRINT® particle technology to design next generation malaria vaccines. PRINT technology offers unprecedented control of particle size, shape and chemistry in a highly consistent and scalable manufacturing process, and will be used to deliver a protein in combination with immune stimulating molecules.
University Hospitals Case Medical Center is the first in Cleveland to implant a new type of cochlear device for adults who have lost the high frequency range of their hearing, but have retained the low frequencies with or without a hearing aid.
The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).
The proposed link between caffeine and reductions in the beta amyloid plaque accumulation characteristic of Alzheimer's disease (AD) suggest a possible role for caffeine in AD treatment. The latest evidence linking beta amyloid protein to Alzheimer's disease and exploring the relationship between caffeine and beta amyloid are featured in a review article in Journal of Caffeine Research: The International Multidisciplinary Journal of Caffeine Science, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Three years ago, the research team directed by Óscar Fernández-Capetillo, head of the Genomic Instability Group at the Spanish National Cancer Research Centre, obtained, for the first time, a panoramic view of the proteins that intervene in one of the most important and delicate cellular processes: the copying of genetic material during cellular division. They observed that the parts of the genome where the DNA was copied were also very rich in the modification by some very particular proteins, SUMOylations, and poor in others, ubiquitinations, but they were unable to understand why.
› Verified 8 days ago
| Provider Name | Wenatchee Valley Hospital |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1669719688 PECOS PAC ID: 9537309869 Enrollment ID: O20130716000034 |
News Archive
Liquidia Technologies today announced a collaboration with the PATH Malaria Vaccine Initiative (MVI) to explore the use of the company's PRINT® particle technology to design next generation malaria vaccines. PRINT technology offers unprecedented control of particle size, shape and chemistry in a highly consistent and scalable manufacturing process, and will be used to deliver a protein in combination with immune stimulating molecules.
University Hospitals Case Medical Center is the first in Cleveland to implant a new type of cochlear device for adults who have lost the high frequency range of their hearing, but have retained the low frequencies with or without a hearing aid.
The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).
The proposed link between caffeine and reductions in the beta amyloid plaque accumulation characteristic of Alzheimer's disease (AD) suggest a possible role for caffeine in AD treatment. The latest evidence linking beta amyloid protein to Alzheimer's disease and exploring the relationship between caffeine and beta amyloid are featured in a review article in Journal of Caffeine Research: The International Multidisciplinary Journal of Caffeine Science, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Three years ago, the research team directed by Óscar Fernández-Capetillo, head of the Genomic Instability Group at the Spanish National Cancer Research Centre, obtained, for the first time, a panoramic view of the proteins that intervene in one of the most important and delicate cellular processes: the copying of genetic material during cellular division. They observed that the parts of the genome where the DNA was copied were also very rich in the modification by some very particular proteins, SUMOylations, and poor in others, ubiquitinations, but they were unable to understand why.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brandon J Child, DPM 820 N Chelan Ave, Wenatchee, WA 98801-2028 Ph: () - | Brandon J Child, DPM 820 N Chelan Ave, Wenatchee, WA 98801-2028 Ph: (509) 663-8711 |
News Archive
Liquidia Technologies today announced a collaboration with the PATH Malaria Vaccine Initiative (MVI) to explore the use of the company's PRINT® particle technology to design next generation malaria vaccines. PRINT technology offers unprecedented control of particle size, shape and chemistry in a highly consistent and scalable manufacturing process, and will be used to deliver a protein in combination with immune stimulating molecules.
University Hospitals Case Medical Center is the first in Cleveland to implant a new type of cochlear device for adults who have lost the high frequency range of their hearing, but have retained the low frequencies with or without a hearing aid.
The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).
The proposed link between caffeine and reductions in the beta amyloid plaque accumulation characteristic of Alzheimer's disease (AD) suggest a possible role for caffeine in AD treatment. The latest evidence linking beta amyloid protein to Alzheimer's disease and exploring the relationship between caffeine and beta amyloid are featured in a review article in Journal of Caffeine Research: The International Multidisciplinary Journal of Caffeine Science, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Three years ago, the research team directed by Óscar Fernández-Capetillo, head of the Genomic Instability Group at the Spanish National Cancer Research Centre, obtained, for the first time, a panoramic view of the proteins that intervene in one of the most important and delicate cellular processes: the copying of genetic material during cellular division. They observed that the parts of the genome where the DNA was copied were also very rich in the modification by some very particular proteins, SUMOylations, and poor in others, ubiquitinations, but they were unable to understand why.
› Verified 8 days ago
Foot & Ankle Center Of Wenatchee, P.s. Podiatrist Medicare: Medicare Enrolled Practice Location: 616 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-662-2970 Fax: 509-665-9808 | |
Dr. Scott A. Schroeder, D.P.M. Podiatrist Medicare: Medicare Enrolled Practice Location: 616 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-662-2970 Fax: 509-665-9808 | |
Dr. Joel D. Hix, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Dr. Tony D. H. Kim, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 616 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-662-2970 Fax: 509-665-9808 | |
Dr. Jac R Tiechner, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 616 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-662-2970 Fax: 509-665-9808 | |
Marjorie Rarama, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 |